Emergent Biosolutions

Emergent BioSolutions is a life sciences company. The company is focused on preparedness and response products and solutions that address the following categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing. The company also has a development pipeline consisting of a mix of both pre-clinical and clinical-stage product candidates, including Trobigard? a combination drug-device auto injector product candidate. In addition, the company has a fully integrated molecule-to-market biologics CDMO business offerings (development services, drug substance and drug product).
  • TickerEBS
  • ISINUS29089Q1058
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
EBS Emergent Biosol... (Health Care)

EMERGENT BIOSOLUTIONS sees an upgrade to Slightly Negative thanks to a...

The independent financial analyst theScreener just awarded an improved star rating to EMERGENT BIOSOLUTIONS (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date July 20, 2021, the closing price was USD 65.12 and its target price was estimated at USD 44.22.

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Release Second Quarter 2021 Financial Results...

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021 GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – tol...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions Announces Positive Two-Year Persistence Data Fro...

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose reflecting persistence of the immune response.The vaccine candidate was well-tolerated. The majority of solicited adverse events were mild or...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders o...

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.   HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record as of the record date of March 25, 2021 are eligible to participate in and ask questions during the Virtual Annual Meeti...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions to Participate in Investor Conferences GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Goldman Sachs Credit and Leveraged Finance ConferenceMay 17, 20211-on-1 meetings only Benchmark Company Healthcare House Call ConferenceMay 26, 20211-on-1 meetings only Singular Research Spring Select Webcall May 27, 2021Company presentation scheduled at 8:00 am Pacific / 11:00 am Eastern For conferences where a ...

EBS Emergent Biosol... (Health Care)

EMERGENT BIOSOLUTIONS sees an upgrade to Slightly Negative thanks to a...

The independent financial analyst theScreener just awarded an improved star rating to EMERGENT BIOSOLUTIONS (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date July 20, 2021, the closing price was USD 65.12 and its target price was estimated at USD 44.22.

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Release Second Quarter 2021 Financial Results...

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021 GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – tol...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions Announces Positive Two-Year Persistence Data Fro...

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose reflecting persistence of the immune response.The vaccine candidate was well-tolerated. The majority of solicited adverse events were mild or...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders o...

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.   HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record as of the record date of March 25, 2021 are eligible to participate in and ask questions during the Virtual Annual Meeti...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions to Participate in Investor Conferences GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Goldman Sachs Credit and Leveraged Finance ConferenceMay 17, 20211-on-1 meetings only Benchmark Company Healthcare House Call ConferenceMay 26, 20211-on-1 meetings only Singular Research Spring Select Webcall May 27, 2021Company presentation scheduled at 8:00 am Pacific / 11:00 am Eastern For conferences where a ...

EBS Emergent Biosol... (Health Care)

EMERGENT BIOSOLUTIONS sees an upgrade to Slightly Negative thanks to a...

The independent financial analyst theScreener just awarded an improved star rating to EMERGENT BIOSOLUTIONS (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date July 20, 2021, the closing price was USD 65.12 and its target price was estimated at USD 44.22.

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Release Second Quarter 2021 Financial Results...

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021 GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – tol...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions Announces Positive Two-Year Persistence Data Fro...

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose reflecting persistence of the immune response.The vaccine candidate was well-tolerated. The majority of solicited adverse events were mild or...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders o...

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.   HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record as of the record date of March 25, 2021 are eligible to participate in and ask questions during the Virtual Annual Meeti...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions to Participate in Investor Conferences GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Goldman Sachs Credit and Leveraged Finance ConferenceMay 17, 20211-on-1 meetings only Benchmark Company Healthcare House Call ConferenceMay 26, 20211-on-1 meetings only Singular Research Spring Select Webcall May 27, 2021Company presentation scheduled at 8:00 am Pacific / 11:00 am Eastern For conferences where a ...

EBS Emergent Biosol... (Health Care)

EMERGENT BIOSOLUTIONS sees an upgrade to Slightly Negative thanks to a...

The independent financial analyst theScreener just awarded an improved star rating to EMERGENT BIOSOLUTIONS (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date July 20, 2021, the closing price was USD 65.12 and its target price was estimated at USD 44.22.

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Release Second Quarter 2021 Financial Results...

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021 GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – tol...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions Announces Positive Two-Year Persistence Data Fro...

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose reflecting persistence of the immune response.The vaccine candidate was well-tolerated. The majority of solicited adverse events were mild or...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders o...

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.   HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record as of the record date of March 25, 2021 are eligible to participate in and ask questions during the Virtual Annual Meeti...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions to Participate in Investor Conferences GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Goldman Sachs Credit and Leveraged Finance ConferenceMay 17, 20211-on-1 meetings only Benchmark Company Healthcare House Call ConferenceMay 26, 20211-on-1 meetings only Singular Research Spring Select Webcall May 27, 2021Company presentation scheduled at 8:00 am Pacific / 11:00 am Eastern For conferences where a ...

EBS Emergent Biosol... (Health Care)

EMERGENT BIOSOLUTIONS sees an upgrade to Slightly Negative thanks to a...

The independent financial analyst theScreener just awarded an improved star rating to EMERGENT BIOSOLUTIONS (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date July 20, 2021, the closing price was USD 65.12 and its target price was estimated at USD 44.22.

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Release Second Quarter 2021 Financial Results...

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021 GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – tol...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions Announces Positive Two-Year Persistence Data Fro...

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose reflecting persistence of the immune response.The vaccine candidate was well-tolerated. The majority of solicited adverse events were mild or...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders o...

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.   HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record as of the record date of March 25, 2021 are eligible to participate in and ask questions during the Virtual Annual Meeti...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions to Participate in Investor Conferences GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Goldman Sachs Credit and Leveraged Finance ConferenceMay 17, 20211-on-1 meetings only Benchmark Company Healthcare House Call ConferenceMay 26, 20211-on-1 meetings only Singular Research Spring Select Webcall May 27, 2021Company presentation scheduled at 8:00 am Pacific / 11:00 am Eastern For conferences where a ...

EBS Emergent Biosol... (Health Care)

EMERGENT BIOSOLUTIONS sees an upgrade to Slightly Negative thanks to a...

The independent financial analyst theScreener just awarded an improved star rating to EMERGENT BIOSOLUTIONS (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date July 20, 2021, the closing price was USD 65.12 and its target price was estimated at USD 44.22.

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Release Second Quarter 2021 Financial Results...

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021 GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021. This conference call can be accessed live by telephone or by webcast: Teleconference Information:Dial in number – tol...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions Announces Positive Two-Year Persistence Data Fro...

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose reflecting persistence of the immune response.The vaccine candidate was well-tolerated. The majority of solicited adverse events were mild or...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders o...

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.   HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record as of the record date of March 25, 2021 are eligible to participate in and ask questions during the Virtual Annual Meeti...

 PRESS RELEASE
EBS Emergent Biosol... (Health Care)

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions to Participate in Investor Conferences GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Goldman Sachs Credit and Leveraged Finance ConferenceMay 17, 20211-on-1 meetings only Benchmark Company Healthcare House Call ConferenceMay 26, 20211-on-1 meetings only Singular Research Spring Select Webcall May 27, 2021Company presentation scheduled at 8:00 am Pacific / 11:00 am Eastern For conferences where a ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch